Candel Therapeutics, Inc.
CADL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001841387
In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Candel Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 23 | 25 | +2 |
| Shares | 6.35M | 6.08M | −264.9K (−4.2%) |
| Value | $20.6M | $19.1M | −$1.46M (−7.1%) |
New holders (4)
Institutions that held Candel Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 16,851 | $53.0K | 0.00% |
| Millennium Management LLC | 14,844 | $47.0K | 0.00% |
| BNP Paribas Arbitrage, SA | 410 | $1.29K | 0.00% |
| China Universal Asset Management Co., Ltd. | 271 | $1.00K | 0.00% |
Sold out (2)
Institutions that held Candel Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Goldman Sachs Group Inc | 10,037 | $33.0K |
| Point72 Hong Kong Ltd | 640 | $2.00K |